Drug intelligence / Profile preview

QLS1128 + ritonavir

Development stage: Unknown
Lead developer: Qilu Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

QLS1128 + ritonavir is an investigational oral combination therapy being developed for the treatment of COVID-19. QLS1128 is a small molecule inhibitor targeting the SARS-CoV-2 3C-like protease (3CLpro), an essential enzyme for viral replication. Ritonavir, a well-established HIV protease inhibitor, is used in this combination as a pharmacokinetic booster to increase the plasma concentration and effectiveness of QLS1128 by inhibiting its metabolism via cytochrome P450 3A4. The primary indication under investigation is mild to moderate COVID-19 infection. The developer and sponsor of clinical trials for this combination is Qilu Pharmaceutical.

Targets

CYP3A4 (Cytochrome P450 3A4)Mpro (3C-like proteinase of SARS-CoV-2)

Beyond the preview

Go deeper on QLS1128 + ritonavir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLS1128 + ritonavir.

Explore the full profile